SynthesisAnnals of the rheumatic diseases2013
Blocking the effects of interleukin-6 in rheumatoid arthritis and other inflammatory rheumatic diseases: systematic literature review and meta-analysis informing a consensus statement.
Synthesis in Annals of the rheumatic diseases, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. It is linked to trial NCT02043548 (Tocilizumab in the Treatment of Refractory Polymyositis and Dermatomyositis), which is not on this map. Cited by 44 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Tocilizumab in the Treatment of Refractory Polymyositis and Dermatomyositis
Who cites it
44 citing papers in PubMed, 2 syntheses or guidelines pooled it, 97 citations in OpenAlex.
- Pooled it
- Effects of IL-6 Signaling Pathway Inhibition on Weight and BMI: A Systematic Review and Meta-Analysis.International journal of molecular sciences · 2020Pooled it
- Sarilumab and Nonbiologic Disease-Modifying Antirheumatic Drugs in Patients With Active Rheumatoid Arthritis and Inadequate Response or Intolerance to Tumor Necrosis Factor Inhibitors.Arthritis & rheumatology (Hoboken, N.J.) · 2017Trial
- Effects of Janus kinase inhibitor tofacitinib on circulating serum amyloid A and interleukin-6 during treatment for rheumatoid arthritis.Clinical and experimental immunology · 2014Trial
- Tocilizumab versus sarilumab among adults hospitalised with COVID-19: target trial emulation across England and Scotland.Nature communications · 2026Article
- Decision on Optimal Combinatorial Therapies in Immune-mediated inflammatory diseases using Systems approaches (DocTIS): protocol for a single-arm, adaptive basket trial in rheumatoid and psoriatic arthritis.Rheumatology advances in practice · 2026Article
- Inflammatory factor Interleukin-6 and its correlation with rheumatoid arthritis: A meta-analysis.Heliyon · 2024Article
- Exploring the therapeutic potential of interleukin-6 receptor blockade in autoimmune diseases using drug target mendelian randomization.Immunogenetics · 2024Article
- Randomized Trial of Tocilizumab in the Treatment of Refractory Adult Polymyositis and Dermatomyositis.ACR open rheumatology · 2022Article
- Article
- Potential Role of Anti-interleukin (IL)-6 Drugs in the Treatment of COVID-19: Rationale, Clinical Evidence and Risks.BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy · 2020Review
- Oral Methioninase for Covid-19 Methionine-restriction Therapy.In vivo (Athens, Greece) · 2020Review
- Tocilizumab for Treatment of Severe COVID-19 Patients: Preliminary Results from SMAtteo COvid19 REgistry (SMACORE).Microorganisms · 2020Article
- The Role of Chronic Inflammatory Bone and Joint Disorders in the Pathogenesis and Progression of Alzheimer's Disease.Frontiers in aging neuroscience · 2020Review
- Nature's Derivative(s) as Alternative Anti-Alzheimer's Disease Treatments.Journal of Alzheimer's disease reports · 2019Review
- Bile acid receptor agonists in primary biliary cholangitis: Regulation of the cholangiocyte secretome and downstream T cell differentiation.FASEB bioAdvances · 2019Article
- Efficacy of subcutaneous tocilizumab in patients with rheumatoid arthritis and systemic sclerosis overlap syndrome: a report of two cases and review of the literature.BMC rheumatology · 2019Article
- Interleukin-6 does not upregulate pro-inflammatory cytokine expression in anRheumatology advances in practice · 2019Article
- Recent insights into targeting the IL-6 cytokine family in inflammatory diseases and cancer.Nature reviews. Immunology · 2018Review
- Ischemia augments alloimmune injury through IL-6-driven CD4Scientific reports · 2018Article
Corrections and comments
- Erratum issuedMurikama, Miho M [corrected to Murakami, Miho]
Authors and funding
16 authors at 13 institutions in 12 countries.
Funding
Abstract
backgroundSuppression of the immunoinflammatory cascade by targeting interleukin 6 (IL-6) mediated effects constitutes a therapeutic option for chronic inflammatory diseases. Tocilizumab is the only IL-6 inhibitor (IL-6i) licensed for rheumatoid arthritis (RA) and juvenile idiopathic arthritis (JIA), but also other agents targeting either IL-6 or its receptor are investigated in various indications.
objectiveTo review published evidence on safety and efficacy of IL-6i in inflammatory diseases.
methodsWe performed systematic literature searches in Medline and Cochrane, screened EULAR and American College of Rheumatology meeting-abstracts, and accessed http://www.clinicaltrials.gov.
resultsComprehensive evidence supports the efficacy of tocilizumab in RA in DMARD-naïve patients, and after DMARD- and TNFi-failure. Randomised comparisons demonstrate superiority of tocilizumab in JIA, but not ankylosing spondylitis (AS). Other indications are currently investigated. Additional IL-6i show similar efficacy; safety generally appears acceptable.
conclusionsIL-6i is effective and safe in RA and JIA, but not in AS. Preliminary results in other indications need substantiation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.